First Wave BioPharma Receives Neutral Rating from H.C. Wainwright
===============
#3b7e1f05 ver:0.05
Cerevel Therapeutics, a company focused on treating neuroscience diseases, reported its financial results for the third quarter of 2023. The company highlighted its broad neuroscience pipeline and upcoming data readouts in 2024. Cerevel is conducting Phase 2 trials for emraclidine in schizophrenia and a Phase 1 trial for Alzheimer's disease psychosis. They are also conducting a Phase 2 trial for tavapadon in Parkinson's disease. The company's cash reserves are expected to support all planned data readouts in 2024 and fund operations until 2026 .
Vistagen Therapeutics provided updates on its clinical programs and financial status during its fiscal year 2024 third quarter financial results call. The company announced the upcoming initiation of Phase 3 trials for its lead program, fasedienol...
#newstr #CerevelTherapeutics #VistagenTherapeutics #CoherusBiosciences #HarrowHealth #FirstWaveBiopharma #HcWainwright #Immunogenx #GastrointestinalTreatments #Latiglutenase #CeliacDisease #Phase3Trials #Fda #CapitalRaise #FinancialResults #StockPerformance